ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED a-SYNUCLEIN AGGREGATES

Omar El-Agnaf; Nour Khaled Majbour; Nishant Vaikath

ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED a-SYNUCLEIN AGGREGATES

Omar El-Agnaf (Inventor), Nour Khaled Majbour (Inventor), Nishant Vaikath (Inventor)

QBRI - Neurological Disorders Research Center

Qatar Foundation for Education, Science, and Community Development

Research output: Patent

Abstract

The present specification provides a monoclonal antibody that specifically binds aggregated, non-phosphorylated α-synuclein and a hybridoma producing it. Also disclosed are methods of generating antibodies that specifically binds aggregated, non-phosphorylated α-synuclein and uses thereof. Uses of anti-α-synuclein antibody in detection and diagnostic assays, and for prophylaxis or therapy of α-synuclein-associated neurodegenerative diseases, are also disclosed.

Original language	English
Patent number	US2023365665
IPC	G01N 33/ 68 A I
Priority date	17/09/21
Publication status	Published - 16 Nov 2023

Cite this

@misc{80299b34f5f64e75a2adc0a32da202bb,

title = "ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED a-SYNUCLEIN AGGREGATES",

abstract = "The present specification provides a monoclonal antibody that specifically binds aggregated, non-phosphorylated α-synuclein and a hybridoma producing it. Also disclosed are methods of generating antibodies that specifically binds aggregated, non-phosphorylated α-synuclein and uses thereof. Uses of anti-α-synuclein antibody in detection and diagnostic assays, and for prophylaxis or therapy of α-synuclein-associated neurodegenerative diseases, are also disclosed.",

author = "Omar El-Agnaf and Majbour, {Nour Khaled} and Nishant Vaikath",

year = "2023",

month = nov,

day = "16",

language = "English",

type = "Patent",

note = "US2023365665; G01N 33/ 68 A I",

}

TY - PAT

T1 - ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED a-SYNUCLEIN AGGREGATES

AU - El-Agnaf, Omar

AU - Majbour, Nour Khaled

AU - Vaikath, Nishant

PY - 2023/11/16

Y1 - 2023/11/16

N2 - The present specification provides a monoclonal antibody that specifically binds aggregated, non-phosphorylated α-synuclein and a hybridoma producing it. Also disclosed are methods of generating antibodies that specifically binds aggregated, non-phosphorylated α-synuclein and uses thereof. Uses of anti-α-synuclein antibody in detection and diagnostic assays, and for prophylaxis or therapy of α-synuclein-associated neurodegenerative diseases, are also disclosed.

AB - The present specification provides a monoclonal antibody that specifically binds aggregated, non-phosphorylated α-synuclein and a hybridoma producing it. Also disclosed are methods of generating antibodies that specifically binds aggregated, non-phosphorylated α-synuclein and uses thereof. Uses of anti-α-synuclein antibody in detection and diagnostic assays, and for prophylaxis or therapy of α-synuclein-associated neurodegenerative diseases, are also disclosed.

M3 - Patent

M1 - US2023365665

ER -

ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED a-SYNUCLEIN AGGREGATES

Abstract

Fingerprint

Cite this